+6 or trisomy 6

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

+6 or trisomy 6

Clinics and Pathology

Note Trisomy 6 (+6) has been reported as the sole cytogenetics aberration in 14 cases of acute myeloid leukaemia (AML) and five cases of myelodysplastic syndrome. Three out of four AML patients with +6 in one series showed AML-M1 morphology and expression of stem cell antigen CD34 on the leukaemic blasts, suggesting that +6 may be associated with a more primitive form of AML. Nevertheless, other reported cases represent a broader spectrum of AML and it is therefore premature to draw conclusion as to whether special morphological and phenotypic features exist in AML with +6.
Intriguingly, +6 as the sole cytogenetics abnormality have been reported in 12 cases of haematological disorders characterized by peripheral blood cytopenia and hypoplastic bone marrow. Among the 12 cases, eight cases showed dysplastic change in the haemopoietic cells, whereas four did not. In two cases of aplastic anaemia with dyserythropoiesis and +6, FISH showed +6 in erythroid as well as myeloid cells, suggesting involvement of an early haemopoietic progenitor cell. The overall survival ranges from 9 - 48 months. In all cases, normal cells without +6 are present, and the percentage of metaphases with +6 ranges from 6.9% to 85%. It is questionable whether such cases should be classified as hypoplastic MDS, based on clonal cytogenetic change of +6, or aplastic anaemia. The pathogenesis of aplastic anaemia is heterogeneous. While an immunological basis for this disorder is established based on response to immunosuppressive therapy, there is also evidence for clonal nature resulting from damage to the haemopoietic stem cell compartment. Indeed clonal chromosomal abnormalities are reported in otherwise typical aplastic anaemia. Furthermore, aplastic anaemia evolving into acute leukaemia is well documented. This is exemplified by the development of AML in a case of aplastic anaemia with +6 and no dysplasia 15 months after initial diagnosis. Although patients with +6 and marrow aplasia were uniformly non-responsive to treatments by steroids and anti-thymocyte globulin (ATG), clinical response to cyclosporine was seen in two cases. There was improvement of platelet count in one case and complete clinical response in another. Taken together, it is plausible that +6 defines a distinctive subtype of aplastic anaemia with mild dysplastic changes, poor response to steroids and ATG therapy, and a propensity for AML transformation.
Rare instances of +6 may be encountered in childhood acute mixed lineage leukaemia, lymphoblastic transformation of chronic myeloid leukaemia, and chronic myeloproliferative disorder.

Phenotype / cell stem origin Three out of four AML patients with +6 in one series showed AML-M1 morphology and expression of stem cell antigen CD34 on the leukaemic blasts, suggesting that +6 may be associated with a more primitive form of AML.

Evolution A case of aplastic anaemia with +6 and no dysplasia showed transformation into AML at 15 months after initial diagnosis.

Prognosis Trisomy 6 may define a distinctive subtype of aplastic anaemia with mild dysplastic changes, poor response to steroids and ATG therapy, and a propensity for AML transformation. More cases need to be collected to substantiate this contention.

Cytogenetics

Complete karyotype showing 47,XY,+6. G-banding with trypsin/Giemsa. The patient is an 81-year old Chinese man who was admitted for myocardial infarction and was found to be anaemic. Physical examination was unremarkable. Blood counts showed: haemoglobin 8.6 g/dL, white cell count 3.2 X 109/L, and platelet count 174 X 109/L. Bone marrow morphology, cytochemistry and immunophenotyping results were consistent with a diagnosis of acute myeloid leukaemia. Chromosome analysis on bone marrow cells showed: 47,XY,+6[2]/46,XY[5].

External links

Other database +6 or trisomy 6 Mitelman database (CGAP - NCBI)

Other database	+6 or trisomy 6	Mitelman database (CGAP - NCBI)

Bibliography

Trisomy 6 associated with aplastic anemia.

Geraedts JP, Haak HL

Human genetics. 1976 ; 35 (1) : 113-115.

PMID 1002160

Correlation between prognosis and bone marrow chromosomal patterns in children with acute nonlymphocytic leukemia: similarities and differences compared to adults.

Benedict WF, Lange M, Greene J, Derencsenyi A, Alfi OS

Blood. 1979 ; 54 (4) : 818-823.

PMID 289424

Chromosome aberrations and prognosis in preleukaemia.

Panani A, Papayannis AG, Sioula E

Scandinavian journal of haematology. 1980 ; 24 (2) : 97-100.

PMID 6929565

Chromosomal alterations in acute leukemia patients studied with improved culture methods.

Testa JR, Misawa S, Oguma N, Van Sloten K, Wiernik PH

Cancer research. 1985 ; 45 (1) : 430-434.

PMID 3855285

Multiple chromosomally distinct cell populations in myelodysplastic syndromes and their possible significance in the evolution of the disease.

Mecucci C, Rege-Cambrin G, Michaux JL, Tricot G, Van den Berghe H

British journal of haematology. 1986 ; 64 (4) : 699-706.

PMID 3801319

Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia.

Appelbaum FR, Barrall J, Storb R, Ramberg R, Doney K, Sale GE, Thomas ED

Experimental hematology. 1987 ; 15 (11) : 1134-1139.

PMID 3315724

Prognostic significance of chromosome analysis in de novo acute myeloid leukemia (AML).

Weh HJ, Kuse R, Hoffmann R, Seeger D, Suciu S, Kabisch H, Ritter J, Hossfeld DK

Blut. 1988 ; 56 (1) : 19-26.

PMID 3422167

Trisomy 6: a recurring cytogenetic abnormality associated with marrow hypoplasia.

Moormeier JA, Rubin CM, Le Beau MM, Vardiman JW, Larson RA, Winter JN

Blood. 1991 ; 77 (6) : 1397-1398.

PMID 2001462

Cytogenetic analysis of hematologic malignancies in Hong Kong. A study of 98 cases.

Chan LC, Kwong YL, Liu HW, Chan TK, Todd D, Ching LM

Cancer genetics and cytogenetics. 1992 ; 62 (2) : 154-159.

PMID 1394102

Trisomy 6 as the sole chromosome abnormality in myeloid disorders.

Jonveaux P, Fenaux P, Berger R

Cancer genetics and cytogenetics. 1994 ; 74 (2) : 150-152.

PMID 8019961

Primary, single, autosomal trisomies associated with haematological disorders. United Kingdom Cancer Cytogenetics Group (UKCCG).

Leukemia research. 1992 ; 16 (9) : 841-851.

PMID 1405715

Trisomy 6 is the hallmark of a dysplastic clone in bone marrow aplasia.

La Starza R, Matteucci C, Crescenzi B, Criel A, Selleslag D, Martelli MF, Van den Berghe H, Mecucci C

Cancer genetics and cytogenetics. 1998 ; 105 (1) : 55-59.

PMID 9689931

Trisomy 6 as a primary karyotypic aberration in hematologic disorders.

Mohamed AN, Varterasian ML, Dobin SM, McConnell TS, Wolman SR, Rankin C, Willman CL, Head DR, Slovak ML

Cancer genetics and cytogenetics. 1998 ; 106 (2) : 152-155.

PMID 9797781

Trisomy 6 in a childhood acute mixed lineage leukemia.

Onodera N, Nakahata T, Tanaka H, Ito R, Honda T

Acta paediatrica Japonica; Overseas edition. 1998 ; 40 (6) : 616-620.

PMID 9893302

Trisomy 6 and double minute chromosomes in a case of chronic myelomonocytic leukemia.

Sambani C, Trafalis DT, Vessalas G, Politis G, Peristeris P, Nakopoulou L, Giannopoulou J, Michaelidis C, Ayoutantis M, Pantelias GE

Cancer genetics and cytogenetics. 1998 ; 106 (2) : 180-181.

PMID 9797788

Trisomy 6 acquired in lymphoid blast transformation of chronic myelocytic leukemia with t(9;22).

Yilmaz Y, Klein R, Qumsiyeh MB

Cancer genetics and cytogenetics. 2003 ; 145 (1) : 86-87.

PMID 12885470

A rapidly progressive chronic myeloproliferative disease with isolated trisomy 6.

Wong KF

Cancer genetics and cytogenetics. 2004 ; 149 (2) : 176-177.

PMID 15036897

Contributor(s)

Written 06-2004 Edmond SK Ma, Thomas SK Wan

Citation

This paper should be referenced as such :
Ma ESK, Wan TSK . +6 or trisomy 6. Atlas Genet Cytogenet Oncol Haematol. June 2004 .
URL : http://AtlasGeneticsOncology.org/Genes/tri6ID1013.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Sep 24 21:07:47 2008

Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

For comments and suggestions or contributions, please contact us

j.l.huret@chu-poitiers.fr.

Note	Trisomy 6 (+6) has been reported as the sole cytogenetics aberration in 14 cases of acute myeloid leukaemia (AML) and five cases of myelodysplastic syndrome. Three out of four AML patients with +6 in one series showed AML-M1 morphology and expression of stem cell antigen CD34 on the leukaemic blasts, suggesting that +6 may be associated with a more primitive form of AML. Nevertheless, other reported cases represent a broader spectrum of AML and it is therefore premature to draw conclusion as to whether special morphological and phenotypic features exist in AML with +6. Intriguingly, +6 as the sole cytogenetics abnormality have been reported in 12 cases of haematological disorders characterized by peripheral blood cytopenia and hypoplastic bone marrow. Among the 12 cases, eight cases showed dysplastic change in the haemopoietic cells, whereas four did not. In two cases of aplastic anaemia with dyserythropoiesis and +6, FISH showed +6 in erythroid as well as myeloid cells, suggesting involvement of an early haemopoietic progenitor cell. The overall survival ranges from 9 - 48 months. In all cases, normal cells without +6 are present, and the percentage of metaphases with +6 ranges from 6.9% to 85%. It is questionable whether such cases should be classified as hypoplastic MDS, based on clonal cytogenetic change of +6, or aplastic anaemia. The pathogenesis of aplastic anaemia is heterogeneous. While an immunological basis for this disorder is established based on response to immunosuppressive therapy, there is also evidence for clonal nature resulting from damage to the haemopoietic stem cell compartment. Indeed clonal chromosomal abnormalities are reported in otherwise typical aplastic anaemia. Furthermore, aplastic anaemia evolving into acute leukaemia is well documented. This is exemplified by the development of AML in a case of aplastic anaemia with +6 and no dysplasia 15 months after initial diagnosis. Although patients with +6 and marrow aplasia were uniformly non-responsive to treatments by steroids and anti-thymocyte globulin (ATG), clinical response to cyclosporine was seen in two cases. There was improvement of platelet count in one case and complete clinical response in another. Taken together, it is plausible that +6 defines a distinctive subtype of aplastic anaemia with mild dysplastic changes, poor response to steroids and ATG therapy, and a propensity for AML transformation. Rare instances of +6 may be encountered in childhood acute mixed lineage leukaemia, lymphoblastic transformation of chronic myeloid leukaemia, and chronic myeloproliferative disorder.
Phenotype / cell stem origin	Three out of four AML patients with +6 in one series showed AML-M1 morphology and expression of stem cell antigen CD34 on the leukaemic blasts, suggesting that +6 may be associated with a more primitive form of AML.
Evolution	A case of aplastic anaemia with +6 and no dysplasia showed transformation into AML at 15 months after initial diagnosis.
Prognosis	Trisomy 6 may define a distinctive subtype of aplastic anaemia with mild dysplastic changes, poor response to steroids and ATG therapy, and a propensity for AML transformation. More cases need to be collected to substantiate this contention.